Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorties are in panic mode! Trying to do major damage control... If not they should be!!! Tsunami coming... get ready!!! There world is about to get flipped upside down and be left with nothing!!! LOAD UP and HOLD ON!!!
I definitely believe we will see a PR this week... possibly even a couple! We have some great news on the way. If the resistance stays low like it was on Friday we could see a nice run up!It's gonna be a great 1st quarter for NVLX!!!
GREEN CLOSE UP over 6% on no news...VERY NICE!!! Just wait until we get some more GREAT NEWS NEXT WEEK!!! You can tell the stock is about to run up again because all the old bashers are starting to come out of the woodwork again to try and scare off new investors. Don't let them scare you out of your shares... it is going to be a STRONG YEAR FOR NVLX!!! LOAD UP and HOLD ON!!!!
So many great things in the works for NVLX right now, just keeps getting better and better every single week that passes! 2015 is going to be an amazing year for this company!!! I'm betting we see a nice news release tomorrow. NVLX is such a bargain at current pps... LOAD UP and HOLD ON!!!!
Looks like another great opportunity for me to load up and add to my position with some Xmas cheapies! Merry Xmas to me!!! Load up and HOLD on!!!!
While i do think we will see a nice spike in pps and volume with a news release let's not forget this is still going to be a marathon not a sprint. NVLX just keeps looking better and better with each week that passes, and keeps adding more and more value to its shareholders. I am super excited for what is to come over the next 6 months to a year for this company, many Milestones will be accomplished and it is really exciting to be a part of it and watch the story unfold chapter by chapter. The NVLX story will have a happy ending for all of us long term investors, but let's not forget it's going to be a LONG story and we are only on Chapter 1 (maybe Chapter 2)... people that are looking for a SHORT read...NVLX isn't the story for you!!! What a great way to close out the year strong for NVLX! Shout Out to Ken W for following through on everything he said he was going to do so far an adding major shareholder value by the end of the year... Ken W is a HUGE asset to the company and I'm really glad he is on board here. It's going to be a GREAT NEW YEAR for all of us NVLX longs!!! LOAD UP and HOLD ON!!!
I AGREE WITH LEON ON THIS 100%!!! Only a matter of time now before FDA APPROVAL. Load up and HOLD on!!!! GO NVLX!!!
Nuvilex, Inc. (NVLX) is up to much more than most are currently aware of, and it only takes a bit of digging to realize it. The company is clearly out to extend the survival time of patients with advanced inoperable pancreatic cancer and it's also clear they're not stopping there. It is the company's diversity with not only pancreatic cancer, but with other cancers and diabetes, that has it positioned for what could potentially be a lucrative deal with a much larger pharmaceutical firm.
Hopefully my funds clear by EOD Monday. I'm picking up another 8K shares! Gotta build up my position before the rest of the world realizes what is going on here!!! Must get more $$$ to get more shares!!! BUY n HOLD!!!
MORE AMAZING NEWS FOR NVLX TODAY!!! Just keeps getting better and better...LOVE IT!!! I think most people still don't even grasp how great this company is and what they have in the works right now. So excited for what is to happen for 2015. The risk level to high potential reward here is unreal!!! Load up and HOLD on!!! NVLX LONG n STRONG!!!
WOW!!! GREAT NEWS FOR NVLX TODAY!!! Things just keep better and better with each week that passes they get closer n closer to accomplishing their next milestone! Today was just a little teaser of what lies ahead in the near future. So happy I found this stock and invested in it before it takes off. I will definitely be adding more shares and building my position up here at the current pricing... it is a steal under .30/share!!! BUY N HOLD!!! NVLX LONG & STRONG!!!
Nuvilex's news is as good as it gets for a biotech with hopes of furthering a pancreatic cancer treatment, and investors couldn't have asked for a more impressive group to support the development of the company's treatment.
Dr. Daniel Von Hoff along with his team at TD2 have been shaping the path of cancer drugs at an alarming rate. With Dr. Von Hoff, Nuvilex gets a man who has been called the "voice of pancreatic cancer," and yes, he's the very same Dr. Daniel Von Hoff who just led Celgene to FDA approval with its drug Abraxane(R) plus gemcitabine, and the same Dr. Von Hoff who began Eli Lilly's clinical trials with Gemzar(R) (gemcitabine) both for advanced inoperable pancreatic cancer, and both became the "gold standard" for the disease.
TD2 is a world-class drug development service, specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible. TD2 calls itself The Precision Oncology CRO(TM) and uses the slogan "Your Drug's Journey Begins Here." TD2 has managed and conducted more than 60 early-mid phase clinical studies and has worked with more than 350 biotech and pharmaceutical companies worldwide, so its interest in Nuvilex is great news for the Maryland biotech's future.
And, when a leading figure in pancreatic cancer, does in fact, choose to work with Nuvilex, he must feel the company's treatment can have an impact on the overall management of a disease that he's played a pivotal role in fighting against for many years now.
It's gonna be a great month for NVLX! I'm definitely adding to my position this week! Buy n Hold!!!!
Things just keep getting better and better for NVLX. So excited for what the next couple months will bring. Load up and Hold on!!!
NVLX support seems to be growing stronger and stronger every day! Definitely starting to gain some momentum here and making it's way back up towards the .30s again. We all know there what's coming soon, looks like a good time to add to my position before it starts running up again. I must get more $$$ to buy more shares! NVLX buy n hold!!!
Things are looking better and better with each day that passes. So much great news being released about NVLX right now and even more behind the scenes that we have yet to hear about. NVLX is still a steal at these prices, I have a feeling we will be back into the .30s very soon (maybe even higher with the right news). Clock is ticking... tick tock... tick tock
Nuvilex gets worldwide license for insulin-producing cells from University of Technology
SILVER SPRING, Md., Oct. 16, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a license with the University of Technology in Sydney, Australia (UTS), that grants Nuvilex the worldwide rights to use human insulin-producing cells, termed “Melligen” cells, developed by Prof. Ann Simpson and her colleagues at UTS for the development of a treatment for insulin-dependent (Type 1 or juvenile-onset) diabetes. Type 1 diabetics are unable to produce the insulin required to transport glucose (blood sugar) from the blood to the inside of cells where it is used as a source of energy. The beta islet cells of the pancreas (Islets of Langerhans) of Type 1 diabetics that normally produce insulin have been destroyed by an autoimmune disease.
Prof. Simpson said of the opportunity to further the Melligen cell line, “I am pleased that after many years of diabetes research at UTS, Nuvilex will now be developing this technology for commercialization to a global market. My team and I are excited by the prospect of working with Nuvilex to eliminate daily injections for insulin-dependent diabetic patients.”
Nuvilex’s CEO and President, Kenneth L. Waggoner, commented, “The execution of this exclusive worldwide license with UTS for the use of the Melligen cells represents a major milestone in Nuvilex’s efforts to develop a treatment for Type 1 diabetes. This is a disease that affects millions of individuals around the world. Some of the complications diabetics suffer from are eye disease, foot and leg problems, kidney disease and cardiovascular disease. These complications can be dangerous and even life-threatening. If we are successful, those inflicted with Type 1 diabetes will be freed from depending on daily insulin injections or the use of insulin pumps as well as the constant need to monitor their blood glucose levels and modify their diets.”
Melligen cells were originally derived from a human liver cancer cell line. Use of the Melligen cells is contingent upon whether they form tumors when implanted into animals — in other words, whether they are tumorigenic. Experiments will be carried out at the University of Veterinary Medicine in Vienna, Austria, under the leadership of Prof. Dr. Walter H. Gunzburg, a Professor of Virology at that university and the Chief Scientific Officer of Nuvilex and the Chairman and Chief Technology Officer of Nuvilex’s partner companies, SG Austria and Austrianova. These experiments are designed to determine whether or not the Melligen cells are tumorigenic. If the Melligen cells prove to be tumorigenic, attempts will be made to genetically modify them so that they are no longer tumorigenic or an alternative non-tumorigenic insulin-producing cell line will be developed.
If the Melligen cells are not tumorigenic, Nuvilex plans to have them encapsulated using the novel and proprietary Cell-in-a-Box(R) cellulose-based live cell technology as part of its planned treatment for diabetes. It is believed that animal testing of the encapsulated Melligen cells will prove that they are capable of producing insulin “on demand” in diabetic animals. As blood glucose levels rise in animals implanted with Melligen cells, these cells will produce increasing amounts of insulin in response. When blood glucose levels fall, less insulin will be produced by the Melligen cells. Ultimately, encapsulated Melligen cells will be placed into patients with Type 1 diabetes where, hopefully, they will serve as a form of “bio-artificial pancreas.” In laboratory studies, Melligen cells have been shown to respond directly to the amount of glucose in their surroundings. They have already been successfully encapsulated using the Cell-in-a-Box(R) technology.
Mr. Waggoner stated further, “Nuvilex’s Cell-in-a-Box(R)-based treatment, which will serve as a type of bio-artificial pancreas, will differ from those being developed by other companies in a number of ways. First, unlike the efforts of other companies, the cells Nuvilex will be using are not obtained from the pancreas – they are not insulin-producing pancreatic beta islet cells. Significant difficulties have been encountered in keeping such islet cells alive and functioning after they have been implanted inside the body. Second, we believe the cellulose-based Cell-in-a-Box(R) capsules are more capable of maintaining the lifespan and function of the encapsulated cells inside the body than are the other cell encapsulation materials, such as alginate (derived from seaweed), used by others. Third, when present in the body, Cell-in-a-Box(R) capsules do not cause irritation or inflammation of surrounding tissues. Fourth, these capsules do not break down even after long periods of time (greater than 2 years) after implantation in the body. Finally, the Cell-in-a-Box(R) capsules do not elicit a response from the body’s immune system that would destroy the capsules and the insulin-producing cells inside them. In our opinion, similar statements cannot be made for other diabetes treatments based on live cell encapsulation that are being developed anywhere in the world in an effort to produce a long-lasting bio-artificial pancreas.”
Top Level management team, World Renowned Doctors and Scientists on board. Things are looking really good for NVLX! They have so many great things in the works right now with massive potential for success. Looks like they are getting all of their ducks in a row and this seems to be a great entry point at these prices!
Interesting Article http://www.otcjournal.com/Hedgies-Drowning-At-Their-High-Water-Marks-Nuvilex-NVLX-Wins/af/archive/20141017-1/
Hedgies Drowning At Their High Water Marks; Nuvilex (NVLX) Wins
Hedge Fund Managers- Drowning At Their High Water Marks
It seems like we might have had the capitulation sell off this week, with the inevitable margin call second leg down, followed by recovery in the markets.
I've been saying this all along- this is not a recession driven bear market. Other parts of the world are having problems, but the US economy remains in a slow growth, low interest rate, low inflation environment.
These kinds of violent corrections have become the norm, and we're getting used to them.
In my view, hedge funds bear a lot of the responsibility for these extreme conditions. It's due to their structure. Have you ever heard the term "High Water Mark" as it refers to hedge funds?
Here's the scoop. Most hedge funds are structured with a minimal management fee which pays the bills. The upside is in the profit participation for the fund manager.
So, if you hear the phrase "2/20" as it relates to their fee structure, it means the fund managers charge a 2% management fee, and 20% of the annual profits- with one caveat- the annual profits are measured from the "High Water Mark".
The means hedge funds don't have any sort of profit sharing upside unless the value of their fund is making a new all time high each and every year.
Therefore, any hedge fund that is long equities going into a correction must go to cash as quickly as possible in a severe correction in order to avoid falling so far below their High Water Mark that they have to wait a year or two to get back there.
It's the 20% share of the profits that makes them multimillionaires, not the 2% management fee.
However, this structure lends itself to highly volatile markets, forcing fund managers to fall all over themselves to both get in and get out when there's momentum one way or the other. Hedge funds can't afford to be out during corrections, and out during rallies.
Imagine you're Joe Hedge fund manger. If you were looking to take advantage of the macro economic environment, it made sense to be short US Treasuries, and long oil. Since it looked like interest rates would start to climb in 2015, being short Treasuries made sense. When interest rates go up, bonds come down.
With ISIS creating turmoil in the Middle East, and the Ukraine crisis, it looked like oil would be headed higher. This is where we were 30 days ago.
So, if you took the capital from shorting bonds and went long oil, you have been crushed as the 10yr fell below 2% and oil prices fell below $80.
Hence, the increased volatility in moving markets. Hedge funds run for cash as quickly as possible so they don't fall too far below their High Water Marks. They are not really protecting their investors. They are protecting their bonuses.
So, what happens in a monster decline? Hedge funds fall so far below their high water marks they simply shut their doors and send everyone their money back. It's easier to liquidate and start a new fund with a new high water mark, rather than try to regain the old one.
Funny- I know there are many great and highly respected hedge fund managers out there, but members of the fund manager hall of fame in my book are all known for their long term "Buy and Hold" strategies.
Warren Buffett, Peter Lynch, Sir John Templeton, Leon Cooper man- these are the great fund managers who have traditionally employed a long term buy and hold strategy with an eye towards the macro climate as a backdrop to be more or less aggressive.
Fear rules the markets. Hedge fund managers cannot afford to be in during big declines, and out during big rallies.
Fear has flushed out the markets, and headlines were the excuse.
The next big fear will be missing the rebound and the markets going on to new highs. They can't afford to be in, then they can't afford to be out.
And, the Winner Is: Nuvilex (NVLX)
The first of my Big 3 has rebounded beautifully, crossing a very important threshold yesterday. I wasn't sure which one would be the winner. I believe they will all find their way back to much higher levels.
It's technical. Nuvliex (NVLX) has been delivering a series of great news releases of late, and the stock has responded in kind. Here's a list.
•Dr. Walter Gunzburg - the original developer of the technology, has taken over as Chief Science Officer
•Dr. Matthias Lohr, co founder of the original technology, has taken over as Chairman of the Scientific Advisory Board
•Nuvilex (NVLX) applies for Orphan Drug status to the FDA for its therapy for Pancreatic Cancer
•Nuvilex (NVLX) secures world wide license for insulin producing cells from University of Technology in Sydney, Australia for use in developing a Diabetes therapy on their platform.
Here's the chart. Circled in black is the dreaded "Death Cross". The point at which the 50 Day Moving Average crossed below the 200 Day Moving Average, signalling the stock was likely to go lower.
Circled in green on the chart is this week's break out above the 50 Day Moving Average- a technical indicator NVXL is back in a nice up trend.
We've had the 10% correction everyone's been looking for. The small cap stocks started correcting in early August, and the whole sector has been decimated.
One by one many stocks will find their bottoms as panic sellers become exhausted, and buyers start to slowly come back.
Of my big three- NVLX, HECC, and STAF- NVLX has won the race so far. NVLX is the first to find its way back above its 50 DMA and be back in a short term up trend.
Lots of other stocks won't be far behind. I believe the market will complete this bottoming process in October, and get back on a good footing in November.
World Renowned Dr. Daniel Von Hoff to Lead Nuvilex’s Clinical Trials
Nuvilex Signs TD2 as Contract Research Organization (CRO)
•Oncology Pioneer Dr. Daniel Von Hoff Agrees to Lead Nuvilex’s Pancreatic Cancer Clinical Trials
•Dr. Von Hoff Developed Eli Lilly’s Gemzar®
•Dr. Von Hoff Developed Celgene’s Abraxane®
•Dr. Von Hoff is the World’s Leading Authority on Pancreatic Cancer & Now He will Lead Nuvilex’s Clinical Trials
•Nuvilex Also Retains TD2 – The Precision Oncology CRO™ for Clinical Trials
The News Released This Morning by NVLX is Industry Changing and it will surely reverberate throughout the biotech community. Celgene investors know just how big Dr. Daniel Von Hoff is… and Nuvilex Investors are about to learn themselves.
Dr. Daniel Von Hoff is changing the path of Pancreatic Cancer research the way Steve Jobs changed the phone. He is called a Drug Development Expert, a Cancer Expert, and World Renowned to name just a few of the adjectives that are Dr. Von Hoff.
Today’s News also named TD2 as the CRO for Nuvilex’s Clinical Trialswhich is Monster news on its own, and it alone should dramatically push the company’s price per share much higher than its current entry.
After all, TD2 or Translational Drug Development, is a world-class drug development service, specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible.
TD2 calls itself “The Precision Oncology CRO™” and uses the slogan “Your Drug’s Journey Beings Here,” so the ONLY news that could overshadow this huge announcement is that:
Dr. Daniel Von Hoff is going to lead the company’s clinical trials.
The Developer of Celgene’s Abraxane® & Eli Lilly’s Gemzar® (gemcitabine) is now going to Lead Nuvilex’s Pancreatic Cancer Trials.
The same developer who has turned into an FDA Approval Machine. As the World’s Leading Expert on Pancreatic Cancer, the FDA seems to approve everything Dr. Von Hoff touches related to the disease!!
The difference at Nuvilex is that Investors can build a sizable position in NVLX below $1… whereas, Celgene Investors had to build a position at $60.00-$112 before the FDA approved Abraxane®.
Expect to see Celgene and Eli Lilly investors flock to buy-in at Nuvilex… and anyone in the industry who knows Dr. Von Hoff will love the entry price at Nuvilex.
In today’s News, Dr. Von Hoff said:
“The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer,” said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. “Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach.”
Another huge headline in today’s News is the availability of the Pancreatic Cancer Research Team (PCRT) which Nuvilex will now have access to with it’s TD2/Dr. Von Hoff relationship.
The PCRT is a consortium of more than 60 pancreatic cancer experts at over 40 study sites (clinics) worldwide focused on the rapid development of novel therapeutics for pancreatic cancer.
The main benefits of running a pancreatic trial using TD2 Inc.’s PCRT:
•Access to the World’s Clinical Experts in Pancreatic Cancer
•Faster Patient Enrollment (site enrollment that is nearly three timesthe national average)
•Efficient Site Start Up (on average, the overwhelming majority of PCRT sites can be up and running within 12 to 14 weeks)
•Experts to provide feedback and guidance for your data and trial design
At SMMG, we have followed and collected data on both Nuvilex and Dr. Daniel Von Hoff for a while now. After Abraxane® was approved, our goal has been to get his take on Cell-in-a-Box® given Dr. Von Hoff is the leading expert in the pancreatic cancer field.
I guess we now know how Dr. Von Hoff feels about Nuvilex’s Pancreatic Cancer treatment, and we look forward to bringing you an interview with this Pioneer in the Oncology arena very soon.
Needless to say we’re fully aware of how monumental this morning’s news is. It’s Amazing! It’s Blockbuster! It’s Game-Changing! Dr. Von Hoff told the Chicago Tribune last year after presenting Abraxane’s® trial results:
“It’s such a tough disease that moving the needle on survival at all is a major accomplishment. It’s been a pretty tough, discouraging area and the overwhelming majority of studies of similar patients have failed to improve survival at all.”
So… having the Leading Pancreatic Cancer expert agreeing to take the lead on Nuvilex’s Clinical Trials must mean he feels that Nuvilex’s treatment can “move the needle on survival.”
Go Google Dr. Daniel Von Hoff alone and combined with search terms likePancreatic Cancer, Celgene, Abraxane®, TGEN, etc. Go do your Due Diligence on Dr. Von Hoff and you WILL get excited about the future of Nuvilex.
We predict Nuvilex won’t stay a penny stock for very much longer!!!
Dr. Von Hoff is a member of the Pancreatic Cancer “Dream Team” and is world renowned for his contributions to pancreatic cancer research in addition to the development of new cancer drugs.
Having Dr. Von Hoff play a leading role in Nuvilex’s clinical trials for advanced, inoperable pancreatic cancer… will almost guarantee FDA approval of it’s Cell-in-a-Box® treatment for the disease.
Dr. Von Hoff started the development of Gemzar® (gemcitabine) for Eli Lilly… which became the “Gold Standard” single agent treatment for advanced pancreatic cancer and has made Eli Lilly many billions of dollars in profits.
Dr. Von Hoff then led Celgene and its drug Abraxane® to FDA approval as the new “Gold Standard” treatment for advanced pancreatic cancer when he not only lead those clinical trials, but got Abraxane® ”Fast Tracked” through the approval process with the FDA.
Dr. Von Hoff was just inducted last month into the Joshua Lederberg Society for his work in developing the drug Abraxane® for advanced pancreatic cancer patients.
Dr. Von Hoff is essentially called the voice of pancreatic cancer. He is the World’s Leading Pancreatic Cancer Oncologist… He is now going to lead Nuvilex through Clinical Trials and having Dr. Von Hoff on board should leave investors asking when… not if… Cell-in-a-Box® will be FDA approved as an advanced pancreatic cancer treatment.
Between Dr. Von Hoff and Dr. Gerald Crabtree… Nuvilex is in very strong hands with two oncologists who know their way around the FDA. Fast Track is a real expectation now.
Translational Drug Development (TD2) is an affiliate of the very successfulTranslational Genomics Research Institute (TGEN) where Dr. Von Hoff is the Physician in Chief and Director.
Nuvilex could not have found and retained a better Contract Research Organization (CRO) to lead its clinical trials.
Definitely great time and price to load up before it starts to run or get bought out. Don't miss the bus!!!
Not time to buy just yet. Pretty sure we will be seeing the low .60s on this soon!
Dr Von Hoff (AKA - The FDA APPROVAL MACHINE)will be starting his work with NVLX next week!!! It's going to be a whole different ball game from here on out!!! Some GREAT things about to happen for NVLX (and it's investors). I'm so glad I picked up some more shares today... now it's time to HOLD on and enjoy the ride!!!
Great Article! Thanks for sharing. Alot of interesting info in there for sure.
This is just my opinion, but I think there is a good chance that they have already received the cells and begun their work. Everyone seems to think that they need to instant message everything to everyone as it is happening or something. Yes they said the cells will arrive and they will begin trials in mid August (which it is not even mid August yet), but they did not say that we will let you know once the cells arrive and let you know once we start our work. I have a strong hunch that the cells are already there and they have already started. I think that the next news release could be positive trial results. The great thing about NVLX is they always follow through with what they say they are going to do... it might take them a little longer than expected sometimes due to things that might cause delays, but hey that's life... especially when dealing with science and biotech. It is not something they they need to rush to meet a deadline, it is more important to take their time and do it right. Just need to sit back, relax and enjoy the ride... we will get there when we get there and when we do... it will be well worth the wait! I am really happy to be accumulating shares and building my position at the current pps. Buy & Hold... NVLX Long n Strong!!!
I can't believe how bad the pps on this stock has just slipped away into the abyss. What is going on here? Can someone please explain why the major sell off???
Looking at taking a decent position in monif soon, but need to wait a bit longer to see how this plays out over the next week. I have a feeling it may be heading into the lower .60s so Im gonna hold off for now. Curious to see what they have to say on this conference call. My concern is that they have some pretty big dilution issues going on.
Calm before the storm! I really like the fact that the stock has been holding up great even with low volume, I have a feeling we are about to get some good news very soon and when we do... things are going to get very interesting. There are so many people out there who still don't get the BIG picture yet of what NVLX can & will become, but they will soon enough. Accumulate and hold.
Just got paid and ready to load up on some more cheap shares! Gotta build up my position before we start heading back into the .30s again!!! I have a feeling not long from now I will be saying I wish I could still get shares in the .30s
Feels like the calm before the storm to me...this volcano is getting ready to blow!!!
I'm sorry but anyone that does their own DD on NVLX will certainly see that this company is NOT a pump n dump!!! IT IS IN FACT A GREAT COMPANY WITH TOP LEVEL MANAGEMENT, WORLD RENOWNED DOCTORS AND SCIENTISTS ON BOARD. To call it a pump n dump is laughable to anyone that does a little research and DD! This tactic may work on an uneducated person, but smart investors who actually do their DD know how great NVLX is and will never be scared off with these foolish statments.
I have researched many biotech stocks and have never been so excited about investing in a stock like NVLX. I have done ridiculous amounts of DD on NVLX and am extremely happy to have taken a substantial long position. Anyone that does their DD will find it easy to see why everyone is so excited about this company and what it will become over the next few months / years. They have top level management (especially Ken Waggoner) as well as the very best doctors & scientists in their fields on board with the vision and determination needed for NVLX succeed. They are putting everything they have into NVLX and they will never let it fail. IMO It's only a matter of time before big pharma steps in and either partners up with them or buys them out. At this stage of the game NVLX is still a ground floor opportunity with massive potential. Despite what some people have to say the 10K looks fine to me and I see no reason for concern with that or the situation involving Dr. Ryan. There is also no concerns with shareholder dilution as some people are screaming about. Everyone should do their own research and DD before they make a decision of whether to get involved or not, don't take the word of others on these message boards that may or may not have ulterior motives. All I can say is I am super happy to be an investor in NVLX and feel very fortunate to have found this stock before everyone else realizes what a hidden gem it really is.
10K looks ok to me. Very thorough. People that have done their DD (like myself) and can actually see the BIG picture here will be the ones rewarded for their belief and support of NVLX. Looks like it's going to be a great month for NVLX! Can't wait to see it all come together over the next year.
It's going to be a really exciting month for NVLX investors! So many great things in the works right now and some major milestones coming up. NVLX has an excellent management team as well as world renowned doctors and scientists on board. So glad for the opportunity to be a part of NVLX and what they are about to achieve. NVLX is truly a diamond in the rough.
Load Load Load the Boat! Love picking up shares at these prices...Love it!!! Accumulate and hold on for the ride!!!
IMO August is going to be an interesting month and the next 6 to 9 months are going to be filled with NVLX achieving some major milestones!!!
Looks like the perfect opportunity to load up on some shares before we see some significant news releases in August. So many great things just around the corner for NVLX, it makes no sense at all to sell right now IMO. It would be like buying a lotto ticket and throwing it away before they read off the numbers only to find out you would have won if you just held on to your ticket!
New York, NY / ACCESSWIRE / July 23, 2014 / Nuvilex, Inc. (OTCQB: NVLX) will begin preclinical studies in early August with its Contract Research Organization (CRO) Translational Drug Development (TD2) to study the first of 4 symptoms associated with pancreatic cancer and other abdominal cancers. In what is essentially the biggest step in Nuvilex's history to date, the company will enter the clinic under its own brand for the first time ever, and it will do so with the highly respected oncology CRO, TD2 and its Chief Development Officer, Dr. Daniel Von Hoff. In the studies, Nuvilex and TD2 will determine what effect the company's pancreatic cancer treatment will have on these symptoms.
Nuvilex's first preclinical study will test the success of the Cell-in-a-Box(R) /ifosfamide combination in slowing the accumulation of ascites fluid in cancer patients -- specifically malignant ascites. This is likely the initial study because in general, the prognosis for patients with malignant ascites is poor. According to the National Cancer Institute, the mean survival time is less than 4 months depending on the type of malignancy.
Malignant ascites is the abnormal accumulation of abdominal fluid due to the direct effects of cancer, and it appears most often in patients with pancreatic, breast, colon, ovarian, uterine and gastrointestinal tract (stomach and intestines) cancers. The fluid itself can contain cancerous cells, which, in turn, can "seed" at various places in the abdomen and form new tumors, so the fluid most continuously be drained from the patient.
Cancer patients that develop ascites deal with significant symptoms including pain, and endure poor quality of life. Nuvilex expects that its treatment can improve the quality of life for patients with pancreatic cancer and other abdominal cancers by slowing down this abnormal accumulation of malignant ascites.
So, now the question we're left with is; can slowing the accumulation of malignant ascites, potentially increase the mean survival time in those patients, and, in turn, can slowing the ascites improve the quality of life and potentially increase the survival rate for patients with advanced, inoperable pancreatic cancer.
It would have a lot more impact if you would actually post the article you are referring to! Just saying... if you are gonna take the time to state this, then why not post the article?
GO NVLX!!!
Well said Pete!!! I couldn't agree with you more!
I like the fact that it was a quiet week without a bunch of PR. I think it's the calm before the storm IMO and we may be in for some substantial news soon. I love accumulating at the current pps so no rush here for me. Im looking for those LONG TERM capital gains anyway. GO NVLX!
GREAT ARTICLE Otsy!!! I read the whole thing top to bottom twice and it just reminds of how great the potential is with NVLX and why I got involved with it in the first place. Think im gonna go back and read it again!
Must get more shares!!! I just added another 7500 shares today at closing at .27 I will probably add some more next week if I can still get them around this price or less.
GO NVLX!!!!